Portfolio
CRISI Medical SystemsCRISI Medical Systems is developing innovative drug-delivery systems designed to improve clinical outcomes and lower healthcare costs by making the administration of intravenous (IV) drugs safer, more accurate and more cost-effective. CRISI's systems are focused on manually injected drugs, which account for roughly half of the 1.3 billion IV medication doses administered annually in the United States. Crisi was acquired by Becton Dickinson (NYSE: BDX). |
|
ecoATMecoATM has developed an ATM-like kiosk that allows users to deposit used cell phones, tablet computers and MP3 players, and receive cash on the spot. The used equipment is recycled in an eco-friendly manner. ecoATM was acquired by OuterWall/CoinStar (NASDAQ: OUTR). |
|
BiomatricaBiomatrica® develops and markets products and technologies for storing and transporting biological samples such as DNA, RNA, proteins, cells, and diagnostic assays without the need for refrigeration. Biomatrica's products are used in areas such as pre-analytical sample collection, biobanking, forensics, and basic research. Acquired by Exact Sciences (NASDAQ: EXAS). |
|
MD RevolutionMD Revolution is a transformational digital health provider delivering a proven high-value, affordable health management service to large patient populations. The service includes comprehensive health screening and genetic evaluation coupled with a predictive intelligence engine which helps clinicians tailor nutritional and lifestyle coaching protocols on an individual basis. Real-time monitoring and interactive counseling help to motivate individuals to achieve measurable improvements in health and wellness. |
|
Tear Film InnovationsTear Film Innovations (TFI) has developed the iLux® Dry Eye Treatment System, a handheld, FDA-cleared device. The iLux system enables eye care professionals to treat evaporative dry eye in less than ten minutes. Evaporative dry eye afflicts more than 30 million adults in the US. TFI has been acquired by Alcon Inc (NASDAQ: ACL). |
|
SutureEaseSutureEase has developed the SecurusEP™ and CrossBow™ fascial closure system for simplifying the closure of laparoscopic trocar wounds. Both products are FDA cleared and currently being marketed.
|
|
InnovegaInnovega is a developing a fully-immersive display technology based on the combination of a proprietary contact lens and associated eyewear. The technology enhances human vision allowing the wearer to simultaneously access digital media while remaining fully engaged in their normal activities. |
|
EndomorphixEndoMorphix is developing a breakthrough, minimally-invasive treatment for obesity called the Slendura™ procedure. The procedure is based on restriction of the stomach using proprietary, flexible instruments passed through the esophagus. No cutting, stapling or permanent modification of the stomach or GI tract is required. The procedure can be done in an office setting without general anesthesia and is easily reversible without surgery. |
|
OmniomeOmniome is developing a proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy. The platform has the potential to advance cancer diagnostics, drive higher fidelity for single-cell applications, and broadly enable clinical sequencing. The technology is able to provide unsurpassed precision of nucleotide and DNA matching by leveraging the polymerase’s natural matching ability. Depending upon the application, Omniome has the potential to deliver lower cost, decreased runtime, and more samples per run. |
|
AlastinAlastin has developed a line of topical products to speed the recovery process and enhance results from cosmetic surgeries as well as ablative and non-ablative rejuvenating procedures. The core technology is based on a proprietary blend of peptides and other ingredients that reinforce the natural regenerating properties of the skin by activating the production of elastin and collagen and recycling the extracellular matrix (ECM). The company is marketing its products directly to dermatologists and plastic surgeons. |
|
